arrow
H

Hans M. Westgeest

Amphia Hospital
H指数:20
被引数:1,913

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era

基于免疫检查点抑制剂时代随机临床试验数据的转移性透明细胞肾细胞癌新预后模型的开发与外部验证:一项预注册分析

2026-09-090
PRE
AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response

基于人工智能的病理组织学分析预测晚期黑色素瘤对检查点抑制剂的反应并识别与反应相关的模式

2026-05-250
OAAI
Health-Related Quality of Life in Adolescents and Young Adults With an Uncertain or Poor Cancer Prognosis: Quantitative Baseline Results of the CORD-AYA Study

癌症预后不确定或不良的青少年和年轻成年人的健康相关生活质量:CORD-AYA研究的定量基线结果

2025-11-210
OAAI
Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumors

老年功能损伤对单药免疫疗法在实体瘤中疗效的影响

2025-10-040
OAAI
Response to letter Re: Impact of Immune-Related Adverse Events on Quality of Life and Physical Functioning in Older Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors

回复信函:关于接受免疫检查点抑制剂治疗的老年实体瘤患者中,免疫相关不良事件对生活质量及躯体功能影响的问题

2025-09-220
PRE
Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors

免疫相关不良事件对接受免疫检查点抑制剂治疗的老年实体瘤患者生活质量及躯体功能的影响

2025-06-070
OA
Deep learning on CT scans to predict checkpoint inhibitor treatment outcomes in advanced melanoma
2024-12-300
OAAI
PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma Patients

PrimerX: 一项贝叶斯多阶段队列嵌入随机试验,评估原发性肿瘤延迟局部治疗联合基于免疫检查点抑制剂的一线治疗在转移性肾细胞癌患者中的作用

2024-12-010
OAAI
Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma

转移性皮肤黑色素瘤的基线肿瘤浸润淋巴细胞模式和对免疫检查点抑制的反应

2024-09-010
OAAI
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol
2024-05-232
OAAI
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

多组学分析将低白蛋白血症确定为转移性黑色素瘤PD-1阻断后不良预后的独立生物标志物

2024-05-164
OAAI
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
2024-02-143
OAAI
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol

基于复发性卵巢癌患者功能性信号转导通路活性的表型指导靶向治疗: STAPOVER研究方案

HELIYON
IF3.6
2024-01-011
OAAI